[{"id":"a826a378-9c3a-48e8-a470-1f272ebe3187","acronym":"KEYNOTE-920","url":"https://clinicaltrials.gov/study/NCT03666273","created_at":"2021-01-18T17:59:20.889Z","updated_at":"2025-02-25T16:08:20.091Z","phase":"Phase 1","brief_title":"Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.","source_id_and_acronym":"NCT03666273 - KEYNOTE-920","lead_sponsor":"Bayer","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bapotulimab (BAY 1905254)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 09/12/2018","start_date":" 09/12/2018","primary_txt":" Primary completion: 06/16/2023","primary_completion_date":" 06/16/2023","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2024-05-27"}]